Dr. Singh on Challenges in Leiomyosarcoma Treatment

Arun S. Singh, MD
Published: Tuesday, Jun 12, 2018



Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the challenges of treating patients with leiomyosarcoma.

Many patients with leiomyosarcoma are diagnosed in later stages of disease. This issue partially stems from the overlap between leiomyosarcoma and fibroids, says Singh. Fibroids, which are smooth muscle growths, are a very prevalent problem in women. Leiomyosarcoma is a smooth muscle cancer, and many women who go in for surgery thinking they have fibroids, come out to find they have leiomyosarcoma.

Singh says that this is the biggest problem in deciding how to treat the disease, as surgery for fibroids differs greatly from surgery for leiomyosarcoma. Additionally, the issue of patients being diagnosed later in their disease course makes intervention more difficult.


Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the challenges of treating patients with leiomyosarcoma.

Many patients with leiomyosarcoma are diagnosed in later stages of disease. This issue partially stems from the overlap between leiomyosarcoma and fibroids, says Singh. Fibroids, which are smooth muscle growths, are a very prevalent problem in women. Leiomyosarcoma is a smooth muscle cancer, and many women who go in for surgery thinking they have fibroids, come out to find they have leiomyosarcoma.

Singh says that this is the biggest problem in deciding how to treat the disease, as surgery for fibroids differs greatly from surgery for leiomyosarcoma. Additionally, the issue of patients being diagnosed later in their disease course makes intervention more difficult.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x